Ovid Therapeutics (OVID) Interest Expenses (2016 - 2026)

Ovid Therapeutics' Interest Expenses history runs 11 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• Quarterly Interest Expenses fell 6.84% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 6.84% YoY) and the FY2025 annual result came in at $91.1 million, up 1.81% from the prior year.
• Interest Expenses was $2.3 million for Q1 2026 at Ovid Therapeutics, down from $17.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $89.5 million in Q4 2024 and bottomed at $62158.0 in Q4 2022.
• A 5-year average of $11.5 million and a median of $2.8 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses plunged 97.4% — and 2023, when it soared 8286.69%.
• Ovid Therapeutics' Interest Expenses stood at $62158.0 in 2022, then surged by 8286.69% to $5.2 million in 2023, then surged by 1616.36% to $89.5 million in 2024, then sank by 80.38% to $17.6 million in 2025, then slumped by 86.9% to $2.3 million in 2026.
• Business Quant data shows OVID's Interest Expenses at $2.3 million in Q1 2026, $17.6 million in Q3 2025, and $2.5 million in Q2 2025.